Takeuchi Makoto
Auditor @ Braizon Therapeutics
Takeuchi Makoto is a seed investor at Braizon Therapeutics focused on Information Technology and Finance. At Yamanouchi and Astellas, engaged in drug discovery research in the areas of inflammation and bone metabolism, and created osteoporosis treatment minodronate and overactive bladder treatment solifenacin. After serving as Director of the Chemical Research Laboratory, Astellas Pharma Research Division, Executive Officer, Research PromotionDivision, and General Manager of the Research Management Division, he became Senior Executive Officer, External Relations Director. In addition, he has been involved in a wide range of industry activities, serving as the Research and Development Committee of the Japan Pharmaceutical Manufacturers Association, the chairman of the Industrial Policy Committee, and the Vice Chairman of the Regenerative Medicine Innovation Forum. He also studied at the University of Pennsylvania (Professor Amos B Smith III) for one year from 2001. Graduated from Toyama Medical and Pharmaceutical University Graduate School of Pharmacy. Lecturer at Seminar on Advanced Drug Discovery Science sponsored by the Pharmaceuticals Promotion Association
- Total investments:
- 4
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Takeuchi Makoto invests in
Stages Takeuchi Makoto invests in
Countries Takeuchi Makoto invests in
Round sizes
Round size
- Seed
- $740k–$20M
Investment Focus
Industry
- Information Technology 2 (50%)
- Finance 1 (25%)
- Medical 1 (25%)
- mHealth 1 (25%)
- Internet 1 (25%)
Stage
- Seed 2 (50%)
- Series A 1 (25%)
- Venture - Series Unknown 1 (25%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Linkage
|
Linkage is a Online health support business and Online specific health guidance. | $4.5M / Series A / Mar 30, 2022 | |
Reiwa Travel
|
Reiwa Travel Company Overview Reiwa Travel is a digital travel agency with the mission to "Design New Travel Experiences." We aim to offer innovative experiences and new societal value in international travel. Since April 2022, we have been offering the international travel booking app 'NEWT'. Our goal is to maximize the digitaltransformation (DX) of booking and management tasks in the travel industry, providing unprecedented “easy, affordable, customizable, and secure” package tours. We are committed to creating social value through the experience of international travel.International Travel Booking App 'NEWT' Service Overview 'NEWT' is an international travel booking app designed to create new travel experiences for new era. It offers an easy booking process, achieves cost-effective pricing, creates customizable trips that meet individual needs, and provides the security that makes travelers feel they made the right choice with NEWT.International Travel Booking App 'NEWT': https://app.adjust.com/iidu9wiWeb version 'NEWT': https://newt.net/ | $20.3M / Seed / Jun 28, 2021 | |
Flyle
|
Flyle provides a cloud based platform for product management helping customers to improve productivity & creativity in product development. | $739.7K / Seed / Jun 01, 2021 | |
Visional
|
Visional is creating a company that promotes industrial digital transformation (DX). It works to solve problems in various fields that will arise in the future and to support Japan's productivity improvement. | $759.7K / Venture - Series Unknown / Jan 08, 2021 |
Co-Investors
About Braizon Therapeutics
Braizon Therapeutics, Inc. was established with the aim of applying and implementing, within the fields of medicine and life science, innovative technology for the delivery of drugs to the brain as the outcome of collaborative research by Professor Kazunori Kataoka from the Graduate School of Engineering/Medicine, the University of Tokyo andProfessor Takanori Yokota from the Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University.
Braizon Therapeutics Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Takeuchi Makoto
Auditor
|
|||
|
Fumikazu Wanibuchi
Director, Clinical Development
|
|||
Mariko Tosu
Co-Founder and Chairperson
|
|||
|
Masato Chiba
Director, Research and Development
|
|||
|
Philip Davy
Director, Business Development
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Featured in Investor Lists
Recommended lists
FAQ
What does Takeuchi Makoto invest in?
Takeuchi Makoto invests primarily in Information Technology, Finance and Medical startups, most often at Seed and Series A stage. Most of the 4 investments tracked by Shizune back companies in Japan. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Takeuchi Makoto's check size?
Takeuchi Makoto typically joins rounds of $740k–$20M at Seed. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Takeuchi Makoto participates in.
When did Takeuchi Makoto last invest?
The most recent investment recorded for Takeuchi Makoto closed in Mar 2022. Shizune tracks 4 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
